- Home
- CABA vs EUDA Comparison
CABA vs EUDA Comparison
Compare CABA & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- EUDA
- Stock Information
- Founded
- CABA 2017
- EUDA 2021
- Country
- CABA United States
- EUDA Singapore
- Employees
- CABA N/A
- EUDA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- EUDA Blank Checks
- Sector
- CABA Health Care
- EUDA Finance
- Exchange
- CABA Nasdaq
- EUDA Nasdaq
- Market Cap
- CABA 132.6M
- EUDA 111.5M
- IPO Year
- CABA 2019
- EUDA N/A
- Fundamental
- Price
- CABA $1.49
- EUDA $1.73
- Analyst Decision
- CABA Strong Buy
- EUDA
- Analyst Count
- CABA 7
- EUDA 0
- Target Price
- CABA $12.43
- EUDA N/A
- AVG Volume (30 Days)
- CABA 1.3M
- EUDA 90.6K
- Earning Date
- CABA 08-07-2025
- EUDA 01-01-0001
- Dividend Yield
- CABA N/A
- EUDA N/A
- EPS Growth
- CABA N/A
- EUDA N/A
- EPS
- CABA N/A
- EUDA N/A
- Revenue
- CABA N/A
- EUDA $4,011,005.00
- Revenue This Year
- CABA N/A
- EUDA $212.19
- Revenue Next Year
- CABA N/A
- EUDA $254.35
- P/E Ratio
- CABA N/A
- EUDA N/A
- Revenue Growth
- CABA N/A
- EUDA 8.22
- 52 Week Low
- CABA $0.99
- EUDA $1.82
- 52 Week High
- CABA $5.83
- EUDA $6.30
- Technical
- Relative Strength Index (RSI)
- CABA 42.02
- EUDA 30.41
- Support Level
- CABA $1.40
- EUDA $2.06
- Resistance Level
- CABA $1.56
- EUDA $2.71
- Average True Range (ATR)
- CABA 0.12
- EUDA 0.29
- MACD
- CABA -0.01
- EUDA -0.04
- Stochastic Oscillator
- CABA 20.83
- EUDA 2.80
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.